



April 26, 2024

Vermont Attorney General's Office  
109 State Street  
Montpelier, VT 05609  
AGO.highcostprescriptiondrugs@vermont.gov

To Whom It May Concern:

As required by 18 V.S.A. § 4637(b), Orchard Therapeutics North America is providing notice of the introduction of a new prescription drug with a Wholesale Acquisition Cost that exceeds the threshold set for a specialty drug under the Medicare Part D program on April 26, 2024. The new product being launched is:

NDC	Product Description
83222-0200-01	Lenmeldy (atidarsagene autotemcel) Suspension for IV Infusion 10 to 20mL containing 1.8 to 11.8 x 10 <sup>6</sup> CD34+ cell/mL, 1 Bag

Sincerely,

DocuSigned by:  
  
B6FAB49940F643F...

Frank Thomas  
President & Chief Operating Officer  
Orchard Therapeutics